When was Enumera Molecular founded?

Enumera Molecular was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Enumera Molecular located?

Enumera Molecular is headquartered in Ann Arbor, United States.

Who is the current CEO of Enumera Molecular?

Matthew Cooper of Enumera Molecular.

How many employees does Enumera Molecular have?

As of Jul 31, 2026, the latest employee count at Enumera Molecular is 16.

Is Enumera Molecular a funded company?

Enumera Molecular is a funded company, having raised a total of $31M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 05, 2022.

When was the latest funding round of Enumera Molecular?

Enumera Molecular's latest funding was a $***** Series B round on Jul 16, 2026, with participation from 0 investor.

Where does Enumera Molecular rank among its competitors?

Enumera Molecular ranks 220th amongst 513 active competitors, of which 156 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Enumera Molecular, which secured $12.3M in Jul, 2026.

Who are the top competitors of Enumera Molecular?

Enumera Molecular's top competitors include Natera, Guardant Health and Myriad Genetics. Among them, Enumera Molecular secured the most recent funding round in July, 2026.

Enumera Molecular - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of liquid biopsy tools. The company manufactures tools for developing rapid, low-cost solutions for the assessment of biomolecules via liquid biopsy.

Key Metrics

Founded Year

2022

Location

Ann Arbor, United States

Stage

Series B

Total Funding

$31M in 2 rounds

Latest Funding Round

Series B, Jul 16, 2026, $*****

Investors

Arboretum Ventures

Ranked

220^th among 513 active competitors

Employee Count

16 as on Jul 31, 2026

Similar Companies

Natera & 653 more

View Enumera Molecular's full profile

Enumera Molecular has raised a total funding of $31M over 2 rounds. Its first funding round was on May 05, 2022. Enumera Molecular has 1 institutional investor.

Here is the list of recent funding rounds of Enumera Molecular:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 16, 2026	4584451	Series B	3227581	4058898	2728127	1818126
May 05, 2022	2760587	Series A	7674466	2856850	Arboretum Ventures	6034492

Access funding benchmarks and valuations. Sign up today!

View details of Enumera Molecular's funding rounds and investors

Enumera Molecular's employee count trend

Enumera Molecular has 16 employees as of Jul 26. Here is Enumera Molecular's employee count trend over the years:

Employee count trend for Enumera Molecular

Uncover Enumera Molecular's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enumera Molecular include Natera, Guardant Health and Myriad Genetics. Here is the list of Top 10 competitors of Enumera Molecular, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Orbimed & 25 others	75/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Kleiner Perkins, Google Ventures & 11 others	70/100
5th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
6th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
7th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
8th	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	RA Capital Management, Perceptive Advisors ... & 65 others	66/100
9th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	66/100
10th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
220th	Enumera Molecular 2022, Ann Arbor (United States), Series B	Developer of liquid biopsy tools	$31M	Arboretum Ventures	33/100